Citi Pharma Limited (PSX: CPHL) reported an 11% decline in its consolidated net profit for the fiscal year ended June 30, 2026, recording Rs790.33m compared to Rs892.04m in the preceding year.
Reflecting this bottom-line compression, basic and diluted earnings per share (EPS) for the year fell to Rs3.46, down from Rs3.90 in FY25. The primary factors weighing on final earnings were rising marketing overheads, elevated financial charges, and higher operating expenses, which offset a 7% top-line revenue expansion.
| Description | FY26 (Rs) | FY25 (Rs) | Change % |
|---|---|---|---|
| Sales - net | 14,075,802,871 | 13,153,521,857 | 7.0% |
| Gross profit | 2,472,941,153 | 2,017,608,318 | 22.6% |
| Profit for the year | 790,333,542 | 892,038,934 | -11.4% |
| Earnings per share (Rs) | 3.46 | 3.90 | -11.3% |
Read the full story on the original publisher’s website.
Open original article